PET imaging in oncology

https://doi.org/10.1053/snuc.2000.7439Get rights and content

The role of positron emission tomography (PET) during the past decade has evolved rapidly from a pure research tool to a methodology of enormous clinical potential. Perhaps the most striking development is the use of PET in oncology. PET imaging is approved in the United States for lung, lymphoma, colon, and melanoma cancer imaging. Data are accumulating rapidly to attest the efficacy of Fluorine-18 fluorodeoxyglucose (FDG) imaging in a wide variety of malignant tumors with sensitivities and specificities often in the high 90s. FDG uptake has been shown in tumors of the head and neck, ovary, breast, musculoskeletal system, and neuroendocrine system as well. The major role of PET has emerged as a reliable method for evaluating and staging recurrent disease. But it also has an important role in differentiating beningn and malignant primary tumors. This has been shown particularly well in the differential diagnosis of solitary lung nodules. Although FDG has emerged as the dominant radiopharmaceutical for PET imaging in oncology, numerous other compounds are being evaluated. It is likely that more specific and efficacious compounds will be introduced during the next decade. F-18, because of its highly favorable physical characteristics, is likely to become the technetium of PET imaging. The next decade will witness an explosive growth of PET technology in oncologic imaging.

References (326)

  • TorizukaT et al.

    Diabetes decreases FDG accumulation in primary lung cancer

    Clin Pos Imag

    (1999)
  • LababedeO et al.

    TNM staging of lung cancer

    A quick reference chart. Chest

    (1999)
  • ValkPE et al.

    Staging non-small cell lung cancer by whole-body positron emission tomographic imaging

    Ann Thorac Surg

    (1995)
  • NestleU et al.

    18 F-deoxyglucose radiotherapy in lung cancer: High impact in patients with atelectasis

    Int J Radiat Oncol Biol Phys

    (1999)
  • PatzEF et al.

    Thoracic nodal staging with PET imaging with FDG in patients with bronchogenic carcinoma

    Chest

    (1995)
  • ScottWJ et al.

    Mediastinal lymph node staging of non-small cell lung cancer: A prospective comparison of computed tomography and positron emission tomography

    J Thorac Cardiovasc Surg

    (1996)
  • AbeY et al.

    Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: Preliminary study of lung cancer

    Int J Radiat Oncol Biol Phys

    (1990)
  • VansteenkisteJF et al.

    Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small cell lung cancer: A prospective pilot study

    Ann Oncol

    (1998)
  • VitolaJV et al.

    Positron emission tomography to stage metastatic colorectal carcinoma to liver

    Am J Surg

    (1996)
  • SchiepersC et al.

    Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging

    Eur J Surg Oncol

    (1995)
  • IdoT et al.

    Flurination with F2. A convenient synthesis of 2-deoxy-2-fluoro-D-glucose

    J Org Chem

    (1977)
  • WarburgO

    The Metabolism of Tumors

  • WarburgO

    On the origin of cancer cells

    Science

    (1956)
  • WeberG

    Enzymology of cancer cells (first part)

    New Engl J Med

    (1977)
  • WeberG

    Enzymology of cancer cells (second part)

    New Engl J Med

    (1977)
  • WeberG

    Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes Memorial Lecture

    Cancer Res

    (1983)
  • WeberMJ et al.

    Molecular events leading to enhanced glucose transport in rous sarcoma virus—transformed cells

  • FlierJS et al.

    Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes

    Science

    (1987)
  • HigashiT et al.

    Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study

    J Nucl Med

    (1997)
  • ReskeSN et al.

    Overexpression of glucose transporter and increased FDG uptake in pancreatic carcinoma

    J Nucl Med

    (1997)
  • BrownRS et al.

    Overexpression of glut-1 glucose transporter in human breast cancer: An immunohistochemical study

    Cancer

    (1993)
  • YounesM et al.

    Overexpression of glut-1 and glut-3 in stage I non-small cell lung cancer is associated with poor survival

    Cancer

    (1997)
  • BrownRS et al.

    Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer

    J Nucl Med

    (1999)
  • KnoxEW et al.

    Hexokinase, differentiation and growth rates of transplanted rat tumors

    Cancer Res

    (1970)
  • MonakhovNK et al.

    Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues

    J Natl Cancer Inst

    (1978)
  • KernKA et al.

    Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose

    Surgery

    (1987)
  • WeberG et al.

    Glucose-6-phosphatase activity in normal, precancerous and neoplastic tissues

    Cancer Res

    (1955)
  • Di ChiroG et al.

    Glucose utilization of cerebral gliomas measured by (18F) fluorodeoxy-glucose and positron emission tomography

    Neurology

    (1982)
  • SomP et al.

    A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection

    J Nucl Med

    (1980)
  • Di ChiroG

    Positron emission tomography using (18F) fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool

    Invest Radiol

    (1987)
  • GallagherBM et al.

    Radiopharmaceuticals XXVII. 18F-labled 2-deoxy-2fluoro-D-Glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: Tissue distribution and imaging studies in animals

    J Nucl Med

    (1977)
  • GallagherBM et al.

    Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of (18F)2-deoxy-2-fluoro-D-glucose

    J Nucl Med

    (1978)
  • SorensonJA et al.

    Nuclear Medicine Tomography: Systems and Services

  • KirchnerPT et al.

    Emission computed tomographic imaging

  • CherrySR et al.

    A high resolution PET scanner for imaging small animals

  • KarpJS et al.

    Continuousslice PENN-PET: A positron tomograph with volume imaging capability

    J Nucl Med

    (1990)
  • State of the Art Clinical Full Positron Emission Tomograph

    System specifications: Model 250

    (1998)
  • HalamaJR

    Imaging in nuclear medicine

  • LandoniC et al.

    Comparison of dual-head coincidence PET vs ring PET in tumor patients

    J Nucl Med

    (1999)
  • YutaniK et al.

    Comparison of dual-head coincidence gamma camera FDG imaging with FDG-PET in detection of breast cancer and axillary lymph node metastasis

    J Nucl Med

    (1999)
  • Cited by (0)

    View full text